☆ 4.5 Letter

Neutralizing antibody and T cell responses to SARS-CoV-2 vaccination in hematopoietic cell transplant recipients

BONE MARROW TRANSPLANTATION (2022)

Related references

Note: Only part of the references are listed.

Article Surgery

COVID-19 in transplant recipients: The Spanish experience

Elisabeth Coll et al.

Summary: This study reported the experience of solid organ and hematopoietic stem cell transplant recipients diagnosed with COVID-19 in Spain until July 13, 2020. The incidence of COVID-19 in transplant recipients was higher than the general population. Most patients required hospitalization, and adjusting immunosuppression could improve survival rates. Risk factors for death included age, lung transplantation, and hospital-acquired COVID-19.

AMERICAN JOURNAL OF TRANSPLANTATION (2021)

Add to Collection

Letter Biophysics

Antibody responses to SARS-CoV2 vaccination in allogeneic hematopoietic stem cell transplant recipients

Anne-Claire Mamez et al.

BONE MARROW TRANSPLANTATION (2021)

Add to Collection

Article Multidisciplinary Sciences

Correlates of protection against SARS-CoV-2 in rhesus macaques

Katherine McMahan et al.

Summary: Adoptive transfer of purified IgG from convalescent macaques protects naive macaques against SARS-CoV-2 infection, and cellular immune responses contribute to protection against rechallenge with SARS-CoV-2. The findings suggest that relatively low antibody titres are sufficient for protection against SARS-CoV-2 in macaques, while higher antibody titres are required for treatment of SARS-CoV-2 infection.

NATURE (2021)

Add to Collection

Article Hematology

Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study

Akshay Sharma et al.

Summary: This study examined the characteristics and outcomes of HSCT recipients after developing COVID-19. It found that recipients of autologous and allogeneic HSCT who develop COVID-19 have poor overall survival rates. Factors such as age, sex, and time since transplantation were associated with higher risk of mortality in HSCT recipients.

LANCET HAEMATOLOGY (2021)

Add to Collection

Letter Hematology

Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose

Evangelos Terpos et al.

BLOOD (2021)

Add to Collection

Article Immunology

Vaccinated and Convalescent Donor-Derived Severe Acute Respiratory Syndrome Coronavirus 2-Specific T Cells as Adoptive Immunotherapy for High-Risk Coronavirus Disease 2019 Patients

Penelope-Georgia Papayanni et al.

Summary: The study demonstrates a causal relationship between the expansion of SARS-CoV-2-specific T cells and disease outcome in COVID-19 patients, with insufficient expansion correlating with adverse outcomes in hospitalized patients. T cells generated from convalescent and vaccinated donors showed functional activity against multiple virus variants, while cells from critical patients failed to expand, mirroring the in vivo failure of specific T-cell immunity in controlling infection.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Editorial Material Hematology

Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT

Rabah Redjoul et al.

LANCET HAEMATOLOGY (2021)

Add to Collection

Letter Medicine, General & Internal

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

Brian J. Boyarsky et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Multidisciplinary Sciences

Exposure to SARS-CoV-2 generates T-cell memory in the absence of a detectable viral infection

Zhongfang Wang et al.

Summary: The study found virus-specific T-cell memory in COVID-19 patients and close contacts. Patients had stronger T cell responses compared to close contacts. Despite lacking detectable infection, close contacts were able to gain T-cell immunity against SARS-CoV-2.

NATURE COMMUNICATIONS (2021)

Add to Collection

Editorial Material Hematology

Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma

Sarah Bird et al.

LANCET HAEMATOLOGY (2021)

Add to Collection

Article Hematology

Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy

Binod Dhakal et al.

BLOOD (2021)

Add to Collection

Letter Medicine, General & Internal

Antibody response after second BNT162b2 dose in allogeneic HSCT recipients

Rabah Redjoul et al.

LANCET (2021)

Add to Collection

Article Oncology

The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment

Evangelos Terpos et al.

Summary: Recent data shows suboptimal antibody response to COVID-19 vaccination in patients with hematological malignancies. Specifically, patients with multiple myeloma (MM) exhibit lower production of neutralizing antibodies (NAbs) after vaccination compared to healthy controls, especially when undergoing treatment with anti-CD38 or belamaf. Timely vaccination, possibly during treatment-free periods, is emphasized for this group of patients.

BLOOD CANCER JOURNAL (2021)

Add to Collection

Article Health Care Sciences & Services

Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study

Paul Naaber et al.

Summary: The study found that antibody levels declined at 12 weeks and 6 months after receiving two doses of BNT162b2 vaccine, with Spike antibody levels at 6 months being similar to those in individuals who received one dose or had recovered from COVID-19. Most individuals developed Spike-specific memory T cell responses, which were lower in those with higher T cell immunosenescence. Antibody response was negatively correlated with age and positively correlated with the total score of vaccination side effects.

LANCET REGIONAL HEALTH-EUROPE (2021)

Add to Collection

Article Medicine, Research & Experimental

Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients

Arne Sattler et al.

Summary: The study analyzed immune responses in kidney transplant recipients after receiving the BNT162b2 vaccine, finding weaker antibody responses in transplant patients compared to healthy individuals and most hemodialysis patients. Additionally, spike-specific T cell responses were significantly reduced in transplant patients, indicating a need for revised vaccination strategies in immunosuppressed individuals.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection

Article Medicine, Research & Experimental

Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset

Shirin Kalimuddin et al.

Summary: The study showed that spike-specific T cells and binding antibodies were detectable 10 days after the first dose of the Pfizer/Bio-NTech BNT162b2 vaccine, suggesting that early T cell and binding antibody responses may induce early protection against COVID-19 compared to receptor blocking or virus neutralizing activity.

MED (2021)

Add to Collection

Article Biotechnology & Applied Microbiology

A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction

Chee Wah Tan et al.

NATURE BIOTECHNOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Hematology

SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein

Michael D. Keller et al.

BLOOD (2020)

Add to Collection

Article Medicine, Research & Experimental

Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation

Gunjan L. Shah et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

Add to Collection

© Peeref 2019-2024. All rights reserved.